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Aristolochic  acid  (AA)  is  considered  to  be a  causative  agent  for  progressive  interstitial  renal
ﬁbrosis,  leading  to AA  nephropathy.  Lysophosphatidic  acid  (LPA)  is a mediator  in  the  onset
of renal  ﬁbrosis.  In  this  study,  we  analyzed  the  molecular  species  of  LPA  and  its  precursor
lysophospholipids  in  kidney  tissue  from  rats  exposed  to AA. Daily  intraperitoneal  injections
of AA for  35  days  to  rats  gave  rise  to ﬁbrosis  in  kidney,  decreased  the  kidney  levels  of LPA,
lysophosphatidylserine  and  lysophosphatidylinositol.  In  rat  renal  cell  lines  (NRK52E  and
NRK49F),  AA-induced  cytotoxicity  was  potentiated  by  Ki16425,  LPA1,3 receptor  antagonist.ysophospholipid
ristolochic acid
ysophosphatidic acid
hronic kidney disease
ibrosis
ephrotoxicity
The  level  of mRNA  encording  -smooth  muscle  actin  was  signiﬁcantly  increased  by  AA-
treatment  only  in  NRK52E  cells,  while  the  mRNA  level  of  collagen  III was  decreased  in  both
NRK52E and  NRK49F  cells.  These  results  suggest  that endogenous  LPA  in rat  kidney  prevents
AA-induced  renal  ﬁbrosis.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. IntroductionThe physiological and pathophysiological roles of
ysophospholipids (LPLs), especially lysophosphatidic acid
Abbreviations: 18S, ribosomal protein S18; AA, aristolochic acid;
-SMA, -smooth muscle actin; LC–MS/MS, liquid chromatogra-
hy–tandem mass spectrometry; GAPDH, glyceraldehyde 3-phosphate
ehydrogenase; LPA, lysophosphatidic acid; LPC, lysophosphatidyl-
holine; LPE, lysophosphatidylethanolamine; LPG, lysophosphatidylglyc-
rol; LPI, lysophosphatidylinositol; LPS, lysophosphatidylserine; lysoPLD,
ysophospholipase D; LPL, lysophospholipid; PLA1, phospholipase A1;
LA2, phospholipase A2; HE, hematoxylin/eosin; AZ, azan Mallory.
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(LPA), have been studied extensively in mammals. LPA
is now recognized as not only an intermediate in syn-
thesis of glycerophospholipids but also an important
lipid mediator [1–3]. Recent rapid progress in liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
with high selectivity and sensitivity has contributed greatly
to the progress of biochemical, physiological and patholog-
ical studies of LPLs [4]. In a unilateral ureteral obstruction
model in rats, we  found higher production of LPA from
lysophosphatidylcholine (LPC) in the swollen renal pelvis
in the ligated kidney than in bladder urine [5]. We  reported
prevention by LPA of Cd2+-induced death of cultured rat
renal proximal epithelial cells (NRK52E) and interstitial
ﬁbroblast cells (NRK49F), suggesting that endogenously
generated LPA protects rats from the renal toxicity of
Cd2+ [6]. However, there is no information on renal
is is an open access article under the CC BY-NC-ND license
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tissue level of LPA in rats that were subjected to renal
injury.
Aristolochic acid (AA) is an alkaloid extracted from
mainly seeds of Aristolochia clematitis and roots of Aris-
tolochia fangchi and Aristolochia manshuriensis. Aristolochia
species are used for treatment for arthritis, gout and
rheumatism [7]. AA was shown to act as an analgesic,
diuretic and anti-inﬂammatory agent [8]. However, AA is
now considered a causative agent for progressive intersti-
tial renal ﬁbrosis and urothelial carcinoma development
in the upper urinary tract. These pathological lesions
developed in seemingly unrelated events. The ﬁrst event
occurred in the 1950s in rural villages in the drainage
basin of the Danube river [9] and the second occurred
in Belgium in young women who had taken slimming
pills including Chinese herbs [10]. Since these events,
the uses of AA-containing medicinal substances and sup-
plements have been banned in many countries. On the
other hand, AA is known to have an inhibitory effect on
phospholipase A2 (PLA2) and to prevent inﬂammatory dis-
eases, such as Clostridium difﬁcile-induced diarrhea-related
events [11]. Therefore, we postulated that chronic AA-
induced nephropathy leads to altered levels of LPA and its
related LPLs in animal body tissues. In this study, we exam-
ined whether AA-nephropathy is accompanied by altered
levels of LPLs in whole kidney tissue of rats.
2. Materials and methods
2.1. Materials
AA, a mixture of AAI and AAII, was purchased from
Across Organics (Geel, Belgium). Ki16425, an LPA1, 3 recep-
tor antagonist, was obtained from Cayman Chemical (Ann
Arbor, MI,  USA). Sepasol RNA I super and polyethylene gly-
col #400 were obtained from Nakarai tesque (Kyoto, Japan).
1-Heptadecanoyl (17:0) LPC, 1-heptadecenoyl (17:1)
lysophosphatidylinositol (LPI), 17:0 lysophosphatidylglyc-
erol (LPG), 17:0 lysophosphatidylethanolamine (LPE), and
17:0 lysophosphatidylserine (LPS) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). 17:0 LPA was
prepared from 17:0 LPC using phospholipase D from Strep-
tomyces chromofuscus as described previously [12]. Egg
yolk phosphatidylcholine (PC), 1-palmitoyl LPC, and 1-
palmitoyl LPA as standards for TLC were obtained from
Funakoshi Co. (Tokyo, Japan). AlzetTM osmotic pumps were
purchased from Durect (Cupertino, CA, USA). Chow (MF)
purchased from Oriental Yeast (Tokyo, Japan) had the fol-
lowing components: powders of wheat, defatted soybean,
alfalfa, defatted rice, defatted bovine milk, soybean oil,
corn, white ﬁsh meal, and beer yeast.
2.2. Animal experiments
Male Wistar/ST rats (4–5 weeks old) were purchased
from Japan SLC (Shizuoka, Japan). The breeding room was
kept at 20–25 ◦C with a light–dark cycle of 12 h each. Rats
were allowed free access to a chow and water through-
out the experimental period. All rats were handled in
accordance with the principles and guidelines of the Exper-
imental Animal Committee of Kyushu University of Healthports 2 (2015) 121–129
and Welfare. The rats were divided into two groups of
6 animals each in three separate experiments and accli-
matized for 1 week. One week later, AA was dissolved in
100% polyethylene glycol #400 at a ﬁnal concentration
of 10 mg/ml and was subcutaneously (with and without
AlzetTM) or intraperioneally injected at 10 mg/kg body
weight daily for 35 days. The sham rats were given the
vehicle solution (1 ml/kg).
2.3. Histological analysis
After AA treatment for 35 days, kidneys were quickly
removed. The kidney slices were ﬁxed with 10% formalde-
hyde and then embedded in parafﬁn. Degrees of renal tissue
injury were evaluated by microscopic observation after
staining with hematoxylin/eosin (HE) and azan Mallory
(AZ).
2.4. Lipid extraction from kidney tissue
The frozen kidney (0.24 ± 0.11 g for 6 rats) was placed
on ice and then de-frosted tissues were homogenized
in a glass homogenizer containing 4 ml  of a mixture
of chloroform–methanol–water at a ﬁnal proportion of
1:2:0.8 (v/v), followed by centrifugation at 1100 × g for
10 min  at 4 ◦C after standing on ice for 2 h. The precipitates
were mixed with 0.5 ml  chloroform, 1 ml  methanol and
1 ml  distilled water, and the mixture was  centrifuged at
1100 × g for 10 min  at 4 ◦C. The supernatants were com-
bined, and the pH was adjusted to 9–10 with 20% NH4OH.
After mixing the supernatant with 1.5 ml  chloroform and
1.5 ml  distilled water, the mixture was  centrifuged at
1100 × g for 10 min  at 4 ◦C. The resultant upper phase
was  withdrawn and mixed with 3 ml  of a mixture of
chloroform–methanol (17:3), followed by centrifugation.
The lower phases were combined for LC–MS/MS of LPC.
The pH of the remaining upper phase was  adjusted to 2–3
with 5 M HCl, and polar acidic LPLs were extracted twice
with 3 ml  of chloroform–methanol mixture (17:3). The
lower phases were combined for LC–MS/MS of LPA, LPG,
LPI and LPS.
Before the lipid extraction, 10 nmol 17:0 LPC, 0.5 nmol
17:0 LPS, 0.5 nmol 17:0 LPG, 0.2 nmol 17:1 LPI and 0.5 nmol
17:0 LPA were added as internal standards for corrections
of efﬁciencies of lipid extraction and electrospray ioniza-
tion. The ﬁrst lipid extract was dried under a stream of
nitrogen gas, and were dissolved in 0.5 ml  of a mixture of
methanol/water (95:5, v/v) containing 5 mM formic acid for
LC–MS/MS. The second lipid extract containing acidic polar
lipids such as LPA, LPS, LPG and LPI were dissolved in 0.1 ml
of a mixture of methanol/water (95:5, v/v) containing 5 mM
formic acid for LC–MS/MS.
2.5. LC–MS/MS of LPLs
LC–MS/MS was  performed on a quadrupole-linear ion-
trap hybrid MS,  4000 QTRAPTM (Applied Biosystems/MDS
Sciex; Concord, ON, Canada), with an Agilent 1100 LC
system combined with an autosampler (HTS PAL, CTC
Analytics, Zwingen, Switzerland), as previously described
[13]. Separation of LPCs in the neutral lipid fractions by
logy Reports 2 (2015) 121–129 123
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Table 1
Renal function in AA-exposed rats.
Sham AA
Urea nitrogen (mmol/l) 5.79 ± 0.27 8.40 ± 0.64*
Creatinine (mol/l) 22.71 ± 1.28 28.76 ± 0.88*T. Tsutsumi et al. / Toxico
C was achieved using an Agilent ZORBAX Eclipse XDB-
18 column (50 mm × 1 mm;  3.5-m particle size silica).
he composition of the mobile phase was methanol/water
4:1, v/v) containing 5 mM ammonium formate, which was
umped at a ﬂow rate of 0.1 ml/min for isocratic elution.
eparation of LPA, LPI, LPG and LPS in the acidic LPL frac-
ion by LC was performed with a Tosoh TSK-ODS-100Z
olumn (150 mm × 2 mm;  5-m particle size silica) devel-
ped with methanol/water (19:1, v/v) containing 5 mM
mmonium formate at a ﬂow rate of 0.22 ml/min in iso-
ratic elution mode. At regular intervals, 5 l aliquots of
est solutions were applied to the mass spectrometer for
nalysis. LPL were analyzed by multiple reaction monitor-
ng (MRM)  in positive ion mode for LPC or in negative ion
ode for LPA, LPS, LPG and LPI, as previously described
13]. In the positive ion MRM,  Q1 and Q3 were set for
he protonated molecular ion and [phosphorylcholine]+ at
/z 184 for LPC. In the negative ion MRM,  Q3 was set to
cyclic glycerol phosphate]− at m/z 153 for LPA, LPG and
PS, [inositolphosphate–H2O]− at m/z 241 for LPI in com-
ination with the deprotonated molecular ion as Q1. The
mounts of the different molecular species of LPC were
alculated from the ratios of their areas of positive ions to
hose of internal standards 17:0 LPC. Similarly, the amounts
f molecular species of LPA, LPI, LPG and LPS were calcu-
ated from the ratios of their peak areas of negative ions
o those of internal standards 17:0 LPA, 17:1 LPI, 17:0 LPG,
nd 17:0 LPS, respectively. Each measurement included a
tandard curve with serial dilutions.
.6. mRNA quantiﬁcation
Total RNAs were extracted using Sepasol RNA I Super
 according to the manufacturer’s manual. A Turbo DNA-
ree kit (Ambion, Austin, TX, USA) was used to remove
ontaminating DNAs from the RNAs obtained. The total
NA level was quantiﬁed by determination of ultravio-
et absorbance at 260 nm,  and its purity was veriﬁed by
easuring the absorbance ratio at 260 and 280 nm.  cDNA
as prepared using ReverTra Ace qPCR RT kit (Toyobo,
saka, Japan). Real time RT-PCR with 50 ng cDNA and
00 nM of each sense and antisense primers in a ﬁnal
olume of 20 l using the Thunderbird Sybr qPCR Mix  (Toy-
bo) were performed in triplicate using a Step one plus
Applied Biosystems, Tokyo, Japan) under PCR cycling con-
itions according to manufacturer’s instructions. Analysis
f glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
or kidney homogenates or ribosomal protein S18 (18S)
NA for renal cell pellets was performed in parallel as a
ousekeeping RNA control to normalize gene expression.
he primers used are shown in Supplementary Table 1.
Supplementary Table 1 related to this article can
e found, in the online version, at doi:10.1016/j.toxrep.
015.02.012.
.7. Cell culture and AA treatmentNRK52 and NRK49F cells were provided by Riken Biore-
ource Center (Ibaragi, Japan) and Health Science Research
esources Bank (Osaka, Japan), respectively. The cells
ere maintained in Dulbecco’s Modiﬁed Eagle’s MediumData are the mean ± S.E. for 4–6 rats/group.
* p < 0.05 compared to the sham.
(DMEM) supplemented with 10% (v/v) fetal calf serum
(FCS) and penicillin/streptomycin and incubated at 37 ◦C
in humidiﬁed atmosphere of 5% CO2 and 95% air. The cells
were seeded in a culture dish with 85 mm in diameter or
96-well culture plate at a density of 2 × 105 cells/ml for 48 h
in DMEM with 10% FCS. Cells were washed with phosphate-
buffered saline twice and were treated with AA and/or
Ki16425 for up to 65 h in DMEM without FCS. Cell viability
was determined by Cell Titer 96 Aqueous one solution cell
proliferation assay (Promega, Fitchburg, WI,  USA).
2.8. Statistical analysis
All data are expressed as means ± S.E. Comparisons
were analyzed by Student’s unpaired t-test, and multiple
comparisons were carried out by using one-way ANOVA
with Tukey’s post hoc test.
3. Results
3.1. Effects of AA-treatment on renal injury
Rats received daily subcutaneous injections of AA, but
not vehicle alone, for 35 days were found to form scab.
The subcutaneous tissue was inﬁltrated with polymor-
phonuclear leukocytes and macrophages (Supplementary
Fig. 1A and B). Under our experimental conditions, this
AA-injection route did not affect the renal function of
rats. Next, we  inserted an AlzetTM osmotic pump into the
subcutaneous tissue according to manufacturer’s instruc-
tions to continuously infuse AA for 4 weeks. However, this
injection technique also did not induce signiﬁcant histo-
logical and biological changes in renal tissues (data not
shown). We  ﬁnally selected intraperitoneal injection of AA
for further experiments because we conﬁrmed previous
reports that this route evoked chronic AA-nephropathy in
mice [14,15].
Supplementary Fig. 1 related to this article can be found,
in the online version, at doi:10.1016/j.toxrep.2015.02.012.
As shown in Table 1, the plasma urea–nitrogen and cre-
atinine values in rats treated with AA for 35 day were
signiﬁcantly higher than those of corresponding sham rats.
After exposure of rats to AA for 35 days, HE staining of
isolated rat kidney revealed apoptosis of epithelial cells,
focal vacuolar changes, and thickening of tubular basement
membrane in the renal tubular region (Fig. 1B). On the rat
without AA-treatment, no abnormalities were observed in
described above area (Fig. 1A). In the interstitial region,
slight lymphocytic inﬁltration was detected in 2 of 6 rats
exposed to AA. In contrast, no remarkable glomerular alter-
ation was  observed in rats treated with and without AA. We
124 T. Tsutsumi et al. / Toxicology Reports 2 (2015) 121–129
Fig. 1. Photomicrographs of renal cortices of rats. Rats were exposed to AA (10 mg/kg/day) or vehicle by daily intraperitoneal injection for 35 days. The
kidneys were excised and stained with HE (A and B) or AZ (C and D). Data are representatives of each group with 4 or 6 test and sham rats. Scale bar = 100 m.
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Fig. 2. Effects of AA on mRNA expression of collagen I, collagen III, collagen IV and -SMA. RNAs were extracted from kidneys of rat that received AA
(10  mg/kg/day) for 35 days. mRNAs encoding collagen I, collagen III, collagen IV and -SMA were quantiﬁed by real-time RT-PCR. Results are means ± S.E.
(n  = 6, 4). *p < 0.05 compared to the sham.
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tig. 3. Effects of AA on total amount and molecular species of ﬁve LPL 
xtracted lipids were analyzed by LC–MS/MS. *p < 0.05 compared to the s
erformed AZ staining to examine whether ﬁbrosis pro-
eeded in the interstitial area. After an exposure of 35 days
ith AA, we found prominent collagen ﬁbers in interstitial
reas around the renal tubules of rats (Fig. 1D).
.2. Effect of AA on mRNA levels of collagens and ˛-SMA
The levels of mRNA encoding collagen I and collagen IV
n the kidney of AA-exposed rats were signiﬁcantly higher
han those of the sham rats (Fig. 2). There was a tendency
f higher mean mRNA levels of collagen III and -SMA in
he kidney of AA-exposed rats, but the mean values did noty tissue of rats. Rats were treated with AA (10 mg/kg/day) for 35 days.
reach to signiﬁcant difference compared to the sham rats
(collagen III; p = 0.06, -SMA; p = 0.09).
3.3. Effects of AA on kidney levels of LPLs
The AA exposure to rats signiﬁcantly lowered renal
tissue levels of total LPA, LPI and LPS compared to the
corresponding sham rats (Fig. 3). The markedly lowered
molecular species levels in the kidney were LPA (16:0, 20:4
and 22:6), LPS (18:0 and 20:4), LPG (18:2), LPI (16:0, 18:0,
18:2, 20:3, 20:4, 20:5, 22:5 and 22:6) and LPC (14:0, 16:0,
16:1, 18:0, 18:2, 18:3 and 20:5).
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Fig. 4. Effects of AA and Ki16425 on cell viability. FCS-starved NRK52E and NRK49F cells were incubated with various concentrations (5, 10, 20 M) of AA and Ki16425 for 24, 48 and 65 h. Cell viability was
determined as described in Section 2. Results are means ± S.E. (n = 3). *p < 0.05 compared to the cells treated with vehicle.
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uantiﬁed by real-time RT-PCR. Results are means ± S.E. (NRK52E; n = 6, N
.4. Effect of Ki16425 on AA-induced cytotoxicity
We  examined whether endogenous LPA is involved in
he regulation of viability of NRK52E cells and NRK49F
ells treated with and without AA for various culture
imes. The populations of the survival cells were reduced
y AA-treatment in a concentration- and time-dependent
anner. The viability of AA-exposed cells treated with
i16425 was not different from that of the AA-exposed
ells treated the vehicle, except for decreased viabilities
bserved with Ki16425 (20 M for 65 h) in NRK52E cells
Fig. 4). The number of the survival cells after treatment of
 M AA was signiﬁcantly decreased by co-incubation with
i16425 for 48 and 65 h in NRK49F cells.
.5. Effects of AA and Ki16425 on mRNA expression of
ollagens and ˛-SMA in NRK52E and NRK49F cells
To obtain information on possibility whether endoge-
ous LPA affects AA-induced renal ﬁbrosis in rats, we
easured the mRNA expression of collagens and -SMA
n cultured rat kidney-derived cells (Fig. 5). Based on the
reliminary experiments with AA (5 or 10 M) for 24, 48
r 65 h, we selected the data obtained with AA 5 M for and -SMA in rat kidney-derived cell lines. RNAs were extracted from
. mRNAs encoding collagen I, collagen III, collagen IV and -SMA were
 n = 4). *p < 0.05 compared to the cells treated with vehicle.
65 h. The level of mRNA encoding -SMA in NRK52E cells
treated with AA at 5 M  were about 8.5-fold higher com-
pared to that in NRK52E cells treated with vehicle alone,
and co-incubation of Ki16425 with AA resulted in no sig-
niﬁcant reduction of AA-increased mRNA level (7.4-fold
increase compared to the Ki16425 alone) in NRK52E cells.
Contrary to our expectation, the expression of collagen III in
NRK52E cell was signiﬁcantly lower in rats treated with AA
5 M compared to the vehicle alone. Treatment of Ki16425
alone resulted in about 2-fold increase in mRNA expression
of collagen III, but caused no effect on AA-induced decrease
in mRNA expression of collagen III.
In NRK49F cells, the expressions of collagens I and col-
lagen III after AA-treatment were signiﬁcantly lower than
those after treatment with the vehicle. There was  no signif-
icant effect of Ki16425 on AA-induced reduction of mRNA
expressions of collagen III. The level of mRNA encoding
-SMA in AA-treated rats was  not signiﬁcantly different
from other groups.4. Discussion
In order to elucidate the pathophysiology of AA
nephropathy in humans, AA has been administered to
ology Re128 T. Tsutsumi et al. / Toxic
various experimental animals. Diverse AA administration
procedures were reported: oral for 3 days [8], 7 days [16]
and 1 month [17], gavage for 3 days [18], intragastric injec-
tion for 12 weeks [19] and subcutaneous injection for 35
days [20]. Among these procedures, we ﬁrst tested the
daily subcutaneous injection at a dose of 10 mg/kg body
weight for 35 days in rats, because this protocol was  devel-
oped renal ﬁbrosis within a relatively short time and its
dose was veriﬁed. However, the procedure produced no
renal lesion, but led to formation of scabs. We  assumed
that formation of the scabs was enhanced by repeated
needle-punctures in narrow area, resulting in the insufﬁ-
cient movement of AA in bloodstream. In rats exposed daily
to AA by intraperitoneal injection for up to 35 days, several
indices of renal injury in the rats were higher than those of
sham rats: plasma levels of urea–nitrogen and creatinine,
ﬁbrosis in interstitial areas observed by histological obser-
vation, and signiﬁcantly higher mRNA levels of collagens I
and IV, but not collagen III and -SMA, in kidney tissue by
real time RT-PCR were signiﬁcantly higher in AA-treated
rats than in sham rats. Similarly, Huang et al. [14] showed
that intraperitoneal injection of AA into mice increases col-
lagens I, III and IV but not -SMA in tubular interstitium and
ﬁbrosis in the region by Masson’s trichrome stain, indicat-
ing a worsening of renal function.
Total LPA, LPS and LPI levels in kidney tissue from
AA-exposed rats were signiﬁcantly lower than those of
the sham rats. PLA2 may  be suppressed by AA-treatment,
leading to a decrease in levels of saturated molecular
species of LPC, LPS and LPI. In addition, phospholipase A1
(PLA1) may  be also suppressed in the kidney by AA treat-
ment, resulting in reduced unsaturated molecular species
of LPA, LPC, LPG, LPS, and LPI. It should be mentioned
that the enzymes for LPI formation were suggested to be
cytosolic calcium-dependent phospholipase A2 and PLA1
[21–23]. AA-treatment probably lowers the kidney lev-
els of various LPLs that express differently homeostatic
actions of the kidney integrity and functions. Gao et al.
[24] showed that intraperitoneal injection of LPA under
ischemia was able to protect against the kidney injury due
to ischemia/reperfusion.
Previously, LPA/LPA1 axis was proposed to be par-
ticipated in renal ﬁbrosis in mice with unilateral ureter
obstruction [25]. Therefore, using rat kidney-derived cells
(NRKE52 and NRK49F) treated with Ki16425, an LPA1,3
antagonist, we examined whether endogenous production
of LPA is involved in AA-induced cell dysfunctions such as
reduced cell viability and stimulated renal ﬁbrosis. In the
latter case, mRNA expressions of collagens (I, III and IV)
and -SMA were selected as marker proteins for extra-
cellular matrix production and epithelial–mesenchymal
transitions, respectively. We  showed that AA-induced
cytotoxicity in NRK52E and NRK49F cells was signiﬁcantly
augmented by treatment with Ki16425, but that treatment
with Ki16425 alone induced no cytotoxicity in the cells.
This result suggests that endogenous LPA protectively acts
as an anti-apoptotic factor against AA-induced cytotoxicity
to the renal cells via LPA1,3 receptors.
We  found that AA-treatment did not increase the mRNA
levels of collagens, but signiﬁcantly increased that of -
SMA  in NRK52E. In NRK 52E cells, AA was reported to
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potentiate the mRNA levels of collagens I and III [26]
and the protein level of -SMA [27]. Although we have
varied the concentration and time of AA-exposure, we
detected no increased mRNA level of collagens under our
experimental conditions. Inconsistency of real time RT-PCR
results with whole kidney and those with NRK52E cells
are unclear at the present time. AA may  indirectly aug-
ment the mRNA expression for collagens through secretion
of endogenous collagen expression-stimulating substances
from renal cells. Another possible factor is its strong cyto-
toxicity of AA toward NRK52E and NRK49F cells, that leads
to reduced mRNA expression of collagen III and collagen I,
but not collagen IV.
Co-incubation of Ki16425 with AA resulted in no addi-
tive or reductive effect in mRNA expressions of collagen
IV and -SMA induced by AA alone, indicating no involve-
ment of endogenous LPA in the AA-induced inhibition of
their mRNA expressions. Interestingly, however, endoge-
nous LPA in NRK52E cells was suggested to signiﬁcantly
inhibit mRNA expression of collagen III in the absence of AA,
whereas it did not affect AA-induced expression of collagen
III mRNA, possibly due to very high inhibitory potency of
AA.
In summary, our results suggest that endogenous LPA in
rat kidney exerts a weak, but signiﬁcant protective effect
on the AA-induced renal ﬁbrosis.
Transparency document
The Transparency document associated with this article
can be found in the online version.
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